GlassScriptPhysician profile
Christopher Tran Bach
NPI 1821313057
$1,179.93
in general payments reported to CMS, 2019-2025
16 companies · $641 in 2025
The $641 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $47.91 · 2021: $41.71 · 2022: $66.93 · 2023: $182 · 2024: $94.57 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.05 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $225.33 | 2023-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $219.79 | 2025 | |
| Boston Scientific Corporation | $161.85 | 2024-2025 | Axios |
| Janssen Scientific Affairs, LLC | $126.92 | 2023 | Stelara |
| Abbvie INC. | $89.92 | 2019-2025 | |
| Pfizer INC. | $89.17 | 2019-2024 | |
| Celgene Corporation | $60.97 | 2022-2023 | Zeposia |
| Amgen INC. | $40.25 | 2025 | |
| Allergan, INC. | $33.60 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $25.31 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $22.36 | 2022 | |
| Merck Sharp & Dohme LLC | $20.83 | 2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $19.70 | 2020 | |
| Portola Pharmaceuticals, LLC | $14.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.